Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hedy Teppler

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
AIDS (London, England)|November 6, 2019
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosisTammy Meyers, Pearl Samson, Edward P Acosta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 20, 2019
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance MutationsAlexander Wong, Deborah Goldstein, Josep Mallolas, et al.
The Lancet. HIV|October 2, 2015
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysisMark A Boyd, Cecilia L Moore, Jean-Michel Molina, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2018
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority TrialPedro Cahn, Paul E Sax, Kathleen Squires, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 16, 2013
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRKJürgen K Rockstroh, Edwin DeJesus, Jeffrey L Lennox, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)Mary A Vogler, Hedy Teppler, Rebecca Gelman, et al.
Plos One|February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Plos One|October 10, 2015
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 InfectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2011
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKJürgen K Rockstroh, Jeffrey L Lennox, Edwin Dejesus, et al.
Journal of the Pediatric Infectious Diseases Society|May 26, 2020
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for TuberculosisPaul Krogstad, Pearl Samson, Edward P Acosta, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
AIDS (London, England)|November 6, 2019
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosisTammy Meyers, Pearl Samson, Edward P Acosta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 20, 2019
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance MutationsAlexander Wong, Deborah Goldstein, Josep Mallolas, et al.
The Lancet. HIV|October 2, 2015
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysisMark A Boyd, Cecilia L Moore, Jean-Michel Molina, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2018
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority TrialPedro Cahn, Paul E Sax, Kathleen Squires, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 16, 2013
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRKJürgen K Rockstroh, Edwin DeJesus, Jeffrey L Lennox, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)Mary A Vogler, Hedy Teppler, Rebecca Gelman, et al.
Plos One|February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Plos One|October 10, 2015
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 InfectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2011
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKJürgen K Rockstroh, Jeffrey L Lennox, Edwin Dejesus, et al.
Journal of the Pediatric Infectious Diseases Society|May 26, 2020
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for TuberculosisPaul Krogstad, Pearl Samson, Edward P Acosta, et al.
Pageof 7